BACKGROUND: Serum levels of melanoma markers may have a role in monitoring disease evolution in metastatic melanoma. PATIENTS AND METHODS: Serial measurements of melanoma inhibiting activity protein (MIA), lactate dehydrogenase (LDH), S-100 and beta2-microglubulin were obtained from 42 metastatic melanoma patients during their biochemotherapy treatment. RESULTS: High pre-treatment serum levels of S-100, LDH, MIA and P2-microglobulin were detected in 50%, 57%, 50% and 24% of the patients, respectively. Only S-100 had prognostic significance for both disease-free (p=0.011) and overall survival (p=0.021). In patients who responded to treatment, S-100 levels decreased significantly from pre-treatment to the time of response (p = 0.050). When patients progressed, levels of MIA and P2-microglobulin increased significantly (p =0.028 and p =0.030, respectively). CONCLUSION: Correlation with disease evolution was found for S-100, MIA and P2-microglobulin levels. Despite the small sample size of the study, S-100 was a significant prognostic marker for overall survival and disease-free survival.
BACKGROUND: Serum levels of melanoma markers may have a role in monitoring disease evolution in metastatic melanoma. PATIENTS AND METHODS: Serial measurements of melanoma inhibiting activity protein (MIA), lactate dehydrogenase (LDH), S-100 and beta2-microglubulin were obtained from 42 metastatic melanomapatients during their biochemotherapy treatment. RESULTS: High pre-treatment serum levels of S-100, LDH, MIA and P2-microglobulin were detected in 50%, 57%, 50% and 24% of the patients, respectively. Only S-100 had prognostic significance for both disease-free (p=0.011) and overall survival (p=0.021). In patients who responded to treatment, S-100 levels decreased significantly from pre-treatment to the time of response (p = 0.050). When patients progressed, levels of MIA and P2-microglobulin increased significantly (p =0.028 and p =0.030, respectively). CONCLUSION: Correlation with disease evolution was found for S-100, MIA and P2-microglobulin levels. Despite the small sample size of the study, S-100 was a significant prognostic marker for overall survival and disease-free survival.
Authors: Maja A Hofmann; Felix Kiecker; Ingeborg Küchler; Christian Kors; Uwe Trefzer Journal: J Cancer Res Clin Oncol Date: 2010-05-09 Impact factor: 4.553
Authors: Angel Díaz-Lagares; Estíbaliz Alegre; Ainhoa Arroyo; María González-Cao; Maria E Zudaire; Santiago Viteri; Salvador Martín-Algarra; Alvaro González Journal: Tumour Biol Date: 2011-08-20
Authors: Pia Vihinen; Minna Kallioinen; Meri-Sisko Vuoristo; Johanna Ivaska; Kari J Syrjänen; Marjo Hahka-Kemppinen; Pirkko-Liisa Kellokumpu-Lehtinen; Seppo O Pyrhönen Journal: Clin Exp Metastasis Date: 2007-08-29 Impact factor: 5.150
Authors: Roberta Balansin Rigon; Márcia Helena Oyafuso; Andressa Terumi Fujimura; Maíra Lima Gonçalez; Alice Haddad do Prado; Maria Palmira Daflon Gremião; Marlus Chorilli Journal: Biomed Res Int Date: 2015-05-11 Impact factor: 3.411
Authors: S Kruijff; E Bastiaannet; A C Muller Kobold; R J van Ginkel; A J H Suurmeijer; H J Hoekstra Journal: Ann Surg Oncol Date: 2009-12 Impact factor: 5.344